{"mainPropery":{"diseaseId":8639,"diseaseName":"Acute disseminated encephalomyelitis","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/8639/acute-disseminated-encephalomyelitis","synonyms":["ADE","ADEM"],"synonyms-with-source":[{"name":"ADE"},{"name":"ADEM"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"83597"},{"identifierType":"UMLS","identifierId":"C0014059"}]},"diseaseCategories":[{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":56,"resourceName":"National Multiple Sclerosis Society","abbreviation":"","address1":"733 Third Avenue, 6th Floor","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10017-3288","country":"United States","phone":"+1-212-986-3240","tty":"","tollFree":"1-800-344-4867","fax":"+1-212-986-7981","email":"nat@nmss.org","url":"https://www.nationalmssociety.org/","freeText":""},{"resourceID":195,"resourceName":"United Leukodystrophy Foundation","abbreviation":"ULF","address1":"224 North Second Street","address2":"Suite 2","address3":"","address4":"","address5":"","city":"DeKalb","state":"IL","zip":"60115 ","country":"United States","phone":"+1-815-748-3211 ","tty":"","tollFree":"1-800-728-5483","fax":"+1-815-748-0844","email":"office@ulf.org","url":"https://ulf.org/","freeText":""},{"resourceID":226,"resourceName":"Siegel Rare Neuroimmune Association","abbreviation":"SRNA","address1":"1787 Sutter Parkway","address2":"","address3":"","address4":"","address5":"","city":"Powell","state":"OH","zip":"43065-8806","country":"United States","phone":"+1-614-317-4884","tty":"","tollFree":"1-855-380-3330 (Helpline)","fax":"","email":"https://www.surveymonkey.com/r/MyelitisHelpLine","url":"https://wearesrna.org/","freeText":"(Formerly the Transverse Myelitis Foundation)"},{"resourceID":933,"resourceName":"American Autoimmune Related Diseases Association","abbreviation":"AARDA","address1":"19176 Hall Road, Suite 130","address2":"","address3":"","address4":"","address5":"","city":"Clinton Township","state":"MI","zip":"48038","country":"United States","phone":"586-776-3900","tty":"","tollFree":"800-598-4668","fax":"586-776-3903","email":"aarda@aarda.org","url":"https://www.aarda.org/","freeText":""},{"resourceID":2437,"resourceName":"Autoimmune Encephalitis Alliance","abbreviation":"","address1":"920 Urban Avenue","address2":"","address3":"","address4":"","address5":"","city":"Durham","state":"NC","zip":"27701","country":"","phone":"","tty":"","tollFree":"","fax":"","email":"https://aealliance.org/contact/","url":"https://aealliance.org/"}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=Acute%5BTitle%5D%20AND%20disseminated%5BTitle%5D%20AND%20encephalomyelitis%5BTitle%5D%20AND%20hasabstract%5Btext%5D%20AND%20English%5BLang%5D%20AND%20%28%22hominidae%22%5BMeSH%20Terms%5D%20OR%20%22Human%22%5BMeSH%20Terms%5D%29' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Acute disseminated encephalomyelitis. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Acute+disseminated+encephalomyelitis%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Acute disseminated encephalomyelitis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1095,"resourceId":1777,"resourceName":"Cleveland Clinic - ADEM","descriptionText":"The <a href='http://my.clevelandclinic.org/disorders/acute_disseminated_encephalomyelitis_adem/hic_overview.aspx ' target='_blank'>Cleveland Clinic</a> provides information about acute disseminated encephalomyelitis (ADEM). Click on the above link to access information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1096,"resourceId":1776,"resourceName":"National Multiple Sclerosis Society - ADEM","descriptionText":"The <a href='http://www.nationalmssociety.org/What-is-MS/Related-Conditions/Acute-Disseminated-Encephalomyelitis-(ADEM)' target='_blank'>National Multiple Sclerosis Society</a> provides information on acute disseminated encephalomyelitis (ADEM). Click on the above link to access information on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1376,"resourceId":2026,"resourceName":"The Cleveland Clinic","descriptionText":"The <a href='https://my.clevelandclinic.org/health/articles/acute-disseminated-encephalomyelitis' target='_blank'>The Cleveland Clinic</a> Web site has an&nbsp;information page on Acute disseminated encephalomyelitis. Click on the Cleveland Clinic link to view this page.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='https://rarediseases.org/rare-diseases/acute-disseminated-encephalomyelitis/' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='https://www.ninds.nih.gov/Disorders/All-Disorders/Acute-Disseminated-Encephalomyelitis-Information-Page' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/1147044-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=83597' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1721,"resourceId":226,"resourceName":"Siegel Rare Neuroimmune Association","descriptionText":"The <a href='http://myelitis.org/symptoms-conditions/acute-disseminated-encephalomyelitis/' target='_blank'>Transverse Myelitis Association</a>&nbsp;provides information about acute disseminated encephalomyelitis (ADEM).","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:639' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2781,"resourceId":4265,"resourceName":"Autoimmune Registry","descriptionText":"The <a href='http://www.autoimmuneregistry.org/' target='_blank'>Autoimmune Registry</a> supports research for Acute disseminated encephalomyelitis by collecting information about patients with this and other autoimmune diseases. You can join the registry to share your information with researchers and receive updates about participating in new research studies.&nbsp;<a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries.</a>","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":1872,"questionText":"What is&nbsp;acute disseminated encephalomyelitis (ADEM)?","answerText":"<strong>Acute disseminated encephalomyelitis (ADEM)</strong> is a&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/neurologicdiseases.html\" target=\"_blank\">neurological condition</a> characterized by a brief but intense attack of inflammation in the brain and spinal cord. This may lead to damage of the layer of insulation around the nerves (myelin) within affected areas.[1146] ADEM often follows viral infection, or less often, vaccinations for <a href=\"http://www.cdc.gov/vaccinesafety/vaccines/mmr-vaccine.html\" target=\"_blank\">measles, mumps, or rubella </a>(MMR).[12053] Symptoms usually appear rapidly, beginning with fever, fatigue, headache, nausea and vomiting.[1146] Treatment for ADEM is targeted at suppressing inflammation in the brain using anti-inflammatory drugs.[1147] Most people begin to recover within days, with total or near-total recovery within a few months. Some people may have lifelong neurological impairments, and very rarely, severe cases can be fatal.[1146]","dateModified":"2017-07-26T00:00:00"},"basicQuestions":[{"questionId":1873,"questionText":"What are the signs and&nbsp;symptoms of acute&nbsp;disseminated encephalomyelitis (ADEM)?","answerText":"The symptoms of ADEM appear quickly, beginning with fever, fatigue, headache, nausea and vomiting, and in severe cases, seizures and coma. Damage to white matter (brain tissue that takes its name from the white color of myelin) may also occur, leading to neurological symptoms such as visual loss, muscle weakness, and difficulty coordinating voluntary muscle movements (such as those used in walking).[1146] &nbsp;<br />\r\n<br />\r\nADEM can be misdiagnosed as a severe first attack of <a href=\"https://rarediseases.info.nih.gov/diseases/10255/multiple-sclerosis\" target=\"_blank\">multiple sclerosis</a> (MS), since some of the symptoms of the two disorders are similar. However, ADEM usually has symptoms of <a href=\"https://medlineplus.gov/encephalitis.html\" target=\"_blank\">encephalitis</a> (such as fever or coma), which are usually not present in MS. In addition, in most cases, ADEM occurs only once, while people with MS have further, repeated attacks of inflammation in their brains and spinal cords.[1146][12053]","dateModified":"2017-07-26T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":1146,"authors":"","articleTitle":"NINDS Acute Disseminated Encephalomyelitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders (NINDS)","date":"","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Acute-Disseminated-Encephalomyelitis-Information-Page","dateAccessed":"2017-07-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12053,"authors":"","articleTitle":"Acute Disseminated Encephalomyelitis (ADEM)","bookWebsiteJournalTitle":"National Multiple Sclerosis Society","date":"","volume":"","pages":"","url":"http://www.nationalmssociety.org/What-is-MS/Related-Conditions/Acute-Disseminated-Encephalomyelitis-(ADEM)","dateAccessed":"2017-07-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1874,"questionText":"What causes&nbsp;acute disseminated encephalomyelitis (ADEM)?","answerText":"The cause of ADEM is not clear. It is thought to be an autoimmune condition in which the body&rsquo;s&nbsp;<a href=\"https://medlineplus.gov/immunesystemanddisorders.html\" target=\"_blank\">immune system</a>&nbsp;mistakenly attacks it's own cells and tissues, resulting in inflammation. It typically develops after a viral or bacterial infection, or less often, after&nbsp;<a href=\"http://www.cdc.gov/vaccinesafety/vaccines/mmr-vaccine.html\" target=\"_blank\">vaccination</a> (immunization). ADEM may occur due to an inflammatory response that is first provoked by the infection or vaccine.[12053][1147]<br />\r\n<br />\r\nMost cases of ADEM occur about 7 to 14 days after an infection, or up to three months following a vaccination.[12053] The most commonly associated infectious agents include <a href=\"https://medlineplus.gov/cytomegalovirusinfections.html\" target=\"_blank\">cytomegalovirus</a> (CMV), <a href=\"https://www.cdc.gov/epstein-barr/about-ebv.html\" target=\"_blank\">Epstein-Barr virus</a>, <a href=\"https://medlineplus.gov/herpessimplex.html\" target=\"_blank\">herpes simplex virus</a>, <a href=\"https://hhv-6foundation.org/what-is-hhv-6\" target=\"_blank\">human herpes-virus-6</a>, <a href=\"https://www.cdc.gov/flu/about/viruses/index.htm\" target=\"_blank\">influenza virus</a>, <a href=\"https://medlineplus.gov/hepatitisa.html\" target=\"_blank\">hepatitis A</a>, <a href=\"https://medlineplus.gov/hivaids.html\" target=\"_blank\">HIV</a>, and <a href=\"https://medlineplus.gov/ency/article/000082.htm\" target=\"_blank\">mycoplasma pneumonia</a>. Associated vaccines have included <a href=\"https://medlineplus.gov/druginfo/meds/a607023.html\" target=\"_blank\">rabies</a>, <a href=\"https://medlineplus.gov/druginfo/meds/a601176.html\" target=\"_blank\">measles</a>, <a href=\"https://medlineplus.gov/tetanusdiphtheriaandpertussisvaccines.html\" target=\"_blank\">pertussis</a>, <a href=\"https://medlineplus.gov/tetanusdiphtheriaandpertussisvaccines.html\" target=\"_blank\">tetanus</a>, influenza, <a href=\"https://medlineplus.gov/ency/article/007613.htm\" target=\"_blank\">hepatitis B</a>, <a href=\"https://medlineplus.gov/tetanusdiphtheriaandpertussisvaccines.html\" target=\"_blank\">diphtheria</a>, <a href=\"https://medlineplus.gov/druginfo/meds/a601176.html\" target=\"_blank\">rubella</a>, <a href=\"https://www.cdc.gov/vaccines/vpd/pneumo/index.html\" target=\"_blank\">pneumococcus</a>, <a href=\"https://www.cdc.gov/vaccines/hcp/vis/vis-statements/varicella.pdf\" target=\"_blank\">varicella</a>, <a href=\"https://www.cdc.gov/smallpox/vaccine-basics/index.html\" target=\"_blank\">smallpox</a>, <a href=\"https://www.cdc.gov/hpv/parents/vaccine.html\" target=\"_blank\">human papillomavirus</a> and <a href=\"https://www.cdc.gov/vaccines/vpd/polio/index.html\" target=\"_blank\">poliomyelitis</a>.[13641]<br />\r\n<br />\r\nIn many cases of ADEM, no preceding infection or \"trigger\" is identified.[1147][12053] Susceptibility to having ADEM may exist and is likely due to multiple factors, including  complex interactions between genetics and exposure to infections and other environmental factors.[1147]","dateModified":"2017-07-26T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":1147,"authors":"Brenton JN","articleTitle":"Acute Disseminated Encephalomyelitis","bookWebsiteJournalTitle":"Medscape Reference","date":"Dec 19, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1147044-overview#showall","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12053,"authors":"","articleTitle":"Acute Disseminated Encephalomyelitis (ADEM)","bookWebsiteJournalTitle":"National Multiple Sclerosis Society","date":"","volume":"","pages":"","url":"http://www.nationalmssociety.org/What-is-MS/Related-Conditions/Acute-Disseminated-Encephalomyelitis-(ADEM)","dateAccessed":"2017-07-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13641,"authors":"Foris L, Dulebohn S","articleTitle":"Disseminated Encephalomyelitis, Acute","bookWebsiteJournalTitle":"StatPearls [Internet]","date":"May 15, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK430934/","authors2":"","placeOfPublication":"Treasure Island (FL)","publisher":"StatPearls Publishing"}]},{"questionId":12057,"questionText":"Is acute disseminated encephalomyelitis (ADEM) inherited?","answerText":"ADEM is not an inherited condition, and we are not aware of any familial cases (reports of ADEM occurring in more than one family member). However, some people may be more susceptible to having ADEM. Susceptibility is likely due to multiple factors, including complex interactions between genetics, exposure to infections, immunization exposure, and other environmental factors.[1147][13641] Because there are no specific genes known to increase a person's risk to have ADEM, there is no \"susceptibility\" test for children who may be at risk, or for parents concerned that current or future children may be at risk.&nbsp;<a href=\"https://rarediseases.info.nih.gov/diseases/8639/acute-disseminated-encephalomyelitis#diseaseCauseSection\" target=\"_blank\">You can read about what is known about possible causes of ADEM here</a>.","dateModified":"2017-07-26T11:39:00","resourceClassificationName":"Inheritance","references":[{"referenceId":1147,"authors":"Brenton JN","articleTitle":"Acute Disseminated Encephalomyelitis","bookWebsiteJournalTitle":"Medscape Reference","date":"Dec 19, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1147044-overview#showall","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13641,"authors":"Foris L, Dulebohn S","articleTitle":"Disseminated Encephalomyelitis, Acute","bookWebsiteJournalTitle":"StatPearls [Internet]","date":"May 15, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK430934/","authors2":"","placeOfPublication":"Treasure Island (FL)","publisher":"StatPearls Publishing"}]},{"questionId":1875,"questionText":"How might acute disseminated encephalomyelitis (ADEM) be treated?","answerText":"Treatment for ADEM aims to suppress inflammation in the brain. Treatment is usually comprised of anti-inflammatory medications. Most individuals respond well to intravenous <a href=\"https://medlineplus.gov/steroids.html\" target=\"_blank\">corticosteroids</a>, such as <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601157.html\" target=\"_blank\">methylprednisolone</a>. When corticosteroids fail to work, <a href=\"http://www.vasculitisfoundation.org/node/486\" target=\"_blank\">plasmapheresis</a> or <a href=\"http://emedicine.medscape.com/article/210367-overview\" target=\"_blank\">intravenous immunoglobulin</a> therapy may be utilized.[1146]","dateModified":"2016-08-16T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":1146,"authors":"","articleTitle":"NINDS Acute Disseminated Encephalomyelitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders (NINDS)","date":"","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Acute-Disseminated-Encephalomyelitis-Information-Page","dateAccessed":"2017-07-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1876,"questionText":"What is the long-term outlook for people with acute&nbsp;disseminated encephalomyelitis (ADEM)?","answerText":"The long-term outlook (prognosis) for people with ADEM varies. Most people begin to recover within days, with total or near-total recovery within a few months. Rarely, there may be some lifelong neurological impairment. Very rarely, ADEM can be fatal.[1146]&nbsp;<br />\r\n<br />\r\nADEM may recur in some cases, and if it does, it is usually within months of the initial episode. Recurrences are typically treated by restarting corticosteroids. A small proportion of people initially diagnosed with ADEM will go on to develop <a href=\"https://rarediseases.info.nih.gov/diseases/10255/multiple-sclerosis\" target=\"_blank\">multiple sclerosis</a> (MS). Unfortunately, there is no way to predict who will develop MS.[1146] The risk for MS appears to be highest in children with ADEM who had no fever, triggering infection, or recent immunization.[1147]","dateModified":"2017-07-26T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":1146,"authors":"","articleTitle":"NINDS Acute Disseminated Encephalomyelitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders (NINDS)","date":"","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Acute-Disseminated-Encephalomyelitis-Information-Page","dateAccessed":"2017-07-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1147,"authors":"Brenton JN","articleTitle":"Acute Disseminated Encephalomyelitis","bookWebsiteJournalTitle":"Medscape Reference","date":"Dec 19, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1147044-overview#showall","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":6895,"relatedDiseaseName":"Leukodystrophy","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":23647,"abbreviatedInquiry":"One of my relatives was diagnosed with acute disseminated encephalomyelitis in 1997. Due to poor medical care, he has not received consistent treatment and his health has deteriorated over the years. He is now completely paralyzed. Is it too late for treatment to be effective? What is the prognosis for an individual who has not been treated promptly?","caseQuestions":[{"questionId":1875,"questionText":"How might acute disseminated encephalomyelitis (ADEM) be treated?","answerText":"Treatment for ADEM aims to suppress inflammation in the brain. Treatment is usually comprised of anti-inflammatory medications. Most individuals respond well to intravenous <a href=\"https://medlineplus.gov/steroids.html\" target=\"_blank\">corticosteroids</a>, such as <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a601157.html\" target=\"_blank\">methylprednisolone</a>. When corticosteroids fail to work, <a href=\"http://www.vasculitisfoundation.org/node/486\" target=\"_blank\">plasmapheresis</a> or <a href=\"http://emedicine.medscape.com/article/210367-overview\" target=\"_blank\">intravenous immunoglobulin</a> therapy may be utilized.[1146]","dateModified":"2016-08-16T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":1146,"authors":"","articleTitle":"NINDS Acute Disseminated Encephalomyelitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders (NINDS)","date":"","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Acute-Disseminated-Encephalomyelitis-Information-Page","dateAccessed":"2017-07-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1876,"questionText":"What is the long-term outlook for people with acute&nbsp;disseminated encephalomyelitis (ADEM)?","answerText":"The long-term outlook (prognosis) for people with ADEM varies. Most people begin to recover within days, with total or near-total recovery within a few months. Rarely, there may be some lifelong neurological impairment. Very rarely, ADEM can be fatal.[1146]&nbsp;<br />\r\n<br />\r\nADEM may recur in some cases, and if it does, it is usually within months of the initial episode. Recurrences are typically treated by restarting corticosteroids. A small proportion of people initially diagnosed with ADEM will go on to develop <a href=\"https://rarediseases.info.nih.gov/diseases/10255/multiple-sclerosis\" target=\"_blank\">multiple sclerosis</a> (MS). Unfortunately, there is no way to predict who will develop MS.[1146] The risk for MS appears to be highest in children with ADEM who had no fever, triggering infection, or recent immunization.[1147]","dateModified":"2017-07-26T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":1146,"authors":"","articleTitle":"NINDS Acute Disseminated Encephalomyelitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders (NINDS)","date":"","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Acute-Disseminated-Encephalomyelitis-Information-Page","dateAccessed":"2017-07-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1147,"authors":"Brenton JN","articleTitle":"Acute Disseminated Encephalomyelitis","bookWebsiteJournalTitle":"Medscape Reference","date":"Dec 19, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1147044-overview#showall","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1878,"questionText":"Is it too late to start proper treatment in order to reverse or stabilize&nbsp;my relative's&nbsp;health?<br />","answerText":"Although we haven't been able to locate any studies which discuss the usefulness of delayed treatment,&nbsp;corticosteroid therapy has been shown to&nbsp;shorten the duration of neurological symptoms and halt further progression of the disease in general.[1146] We recommend that you discuss your concerns with a healthcare provider familiar with the details of your relative's case.&nbsp;","dateModified":"2016-08-16T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":1146,"authors":"","articleTitle":"NINDS Acute Disseminated Encephalomyelitis Information Page","bookWebsiteJournalTitle":"National Institute of Neurological Disorders (NINDS)","date":"","volume":"","pages":"","url":"https://www.ninds.nih.gov/Disorders/All-Disorders/Acute-Disseminated-Encephalomyelitis-Information-Page","dateAccessed":"2017-07-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":1877,"questionText":"What is the prognosis for individuals with acute disseminated encephalomyelitis (ADEM) who do not receive treatment in a timely manner?","answerText":"Early treatment one of the most important factors to determine the prognosis for individuals with ADEM.[1148] However, it is not known whether any available form of treatment effects the time to recovery or the risk for complications.[1147]","dateModified":"2016-08-16T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":1147,"authors":"Brenton JN","articleTitle":"Acute Disseminated Encephalomyelitis","bookWebsiteJournalTitle":"Medscape Reference","date":"Dec 19, 2016","volume":"","pages":"","url":"http://emedicine.medscape.com/article/1147044-overview#showall","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1148,"authors":"Tosun A, Serdaroglu G, Polat M, Tekgul H, Gokben S","articleTitle":"Evaluation of the cases with acute disseminated encephalomyelitis","bookWebsiteJournalTitle":"Indian J Pediatr","date":"2009","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/pubmed/19390813","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Acute_disseminated_encephalomyelitis"}